Patents by Inventor Karen Ferrante

Karen Ferrante has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
    Patent number: 9808472
    Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: November 7, 2017
    Assignees: Tokai Pharmaceuticals, Inc., University of Washington, University of Maryland, Baltimore
    Inventors: Vincent C. O. Njar, Amina Zoubeidi, Karen Ferrante, Eva Corey, Douglas Jacoby
  • Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
    Patent number: 9387216
    Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: July 12, 2016
    Assignees: Tokai Pharmaceuticals, Inc., University of Washington, University of Maryland, Baltimore
    Inventors: Vincent C. O. Njar, Amina Zoubeidi, Karen Ferrante, Eva Corey, Douglas B. Jacoby
  • BIOMARKERS FOR TREATMENT OF NEOPLASTIC DISORDERS USING ANDROGEN-TARGETED THERAPIES
    Publication number: 20160038511
    Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.
    Type: Application
    Filed: August 12, 2014
    Publication date: February 11, 2016
    Applicant: TOKAI PHARMACEUTICALS, INC.
    Inventors: Vincent C.O. Njar, Amina Zoubeidi, Karen Ferrante, Eva Corey, Dr. Douglas Jacoby
  • BIOMARKERS FOR TREATMENT OF NEOPLASTIC DISORDERS USING ANDROGEN-TARGETED THERAPIES
    Publication number: 20150374721
    Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.
    Type: Application
    Filed: July 6, 2015
    Publication date: December 31, 2015
    Inventors: Vincent Njar, Amina Zoubeidi, Karen Ferrante, Eva Corey, Douglas Jacoby
  • Combination therapy for hyperproliferative disease
    Publication number: 20070197517
    Abstract: This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a therapeutically effective amount of a taxane derivative, a platinium coordination complex selected from the group consisting of carboplatin, tetraplatin, and topotecan, a nucleoside analog selected from the group consisting of gemcitabine hydrochloride and 5-FU, an anthracycline, a topoisomerase selected from the group consisting of etoposide, teniposide, amsacrine, topotecan, and Camptosar®, an aromatase inhibitor; and (ii) a therapeutically effective amount of an isothiazole derivative. The combinations of the present invention may optionally include an anti-hypertensive agent.
    Type: Application
    Filed: August 19, 2003
    Publication date: August 23, 2007
    Inventors: Jitesh Jani, Jean Beebe, Tracey Schaeffer, Diane Healey, Karen Ferrante, James O'Leary
  • Stable polymorph of N-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
    Publication number: 20050090500
    Abstract: The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
    Type: Application
    Filed: November 18, 2004
    Publication date: April 28, 2005
    Inventors: Timothy Norris, Jeffrey Raggon, Richard Connell, James Moyer, Michael Morin, Shama Kajiji, Barbara Foster, Karen Ferrante, Sandra Silberman